别名 CD163、CD163 antigen、CD163 molecule + [7] |
简介 Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.
After shedding, the soluble form (sCD163) may play an anti-inflammatory role, and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions. |
靶点 |
作用机制 CD163抑制剂 |
在研机构- |
原研机构 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 泰国 |
首次获批日期1997-01-01 |
靶点 |
作用机制 CD163抑制剂 |
在研机构- |
原研机构- |
在研适应症- |
非在研适应症- |
最高研发阶段临床阶段不明 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 CD163抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2021-09-09 |
申办/合作机构 |
开始日期2020-12-01 |
申办/合作机构- |
开始日期2020-11-11 |
申办/合作机构- |